Dyadic International Inc. (NASDAQ:DYAI) Sees Large Increase in Short Interest

Dyadic International Inc. (NASDAQ:DYAI) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 164,738 shares, a growth of 211.0% from the July 30th total of 52,977 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 206,606 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of Dyadic International

A number of institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares in the last quarter. BlackRock Inc. purchased a new position in Dyadic International during the second quarter valued at approximately $177,000. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the 3rd quarter worth $190,000. Finally, Bank of America Corp DE boosted its position in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the last quarter. Institutional investors own 27.95% of the company’s stock.

Dyadic International Stock Down 3.9%

Shares of DYAI traded down $0.03 on Friday, reaching $0.61. The stock had a trading volume of 276,696 shares, compared to its average volume of 179,838. Dyadic International has a 12-month low of $0.60 and a 12-month high of $1.60. The firm has a market capitalization of $22.38 million, a price-to-earnings ratio of -2.67 and a beta of 1.12. The company has a debt-to-equity ratio of 4.08, a quick ratio of 1.65 and a current ratio of 1.65. The company has a 50-day simple moving average of $0.96 and a 200-day simple moving average of $0.85.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%.The business had revenue of $0.96 million during the quarter, compared to the consensus estimate of $1.02 million. Sell-side analysts predict that Dyadic International will post -0.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.